An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.
D000328:Adult; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D003424:Crohn Disease / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000378:metabolism / Q000627:therapeutic use*; D053762:Interleukin-12 Subunit p40; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D011446:Prospective Studies; D021122:Protein Subunits / Q000378:metabolism / Q000627:therapeutic use*; D018123:Receptors, Interleukin / Q000378:metabolism; D053707:Receptors, Interleukin-12; D011993:Recombinant Fusion Proteins / Q000378:metabolism / Q000627:therapeutic use*; D014302:Trinitrobenzenesulfonic Acid
D007074:Immunoglobulin G; D053762:Interleukin-12 Subunit p40; D021122:Protein Subunits; D018123:Receptors, Interleukin; D053707:Receptors, Interleukin-12; D011993:Recombinant Fusion Proteins; D018664:Interleukin-12; D007371:Interferon-gamma; D014302:Trinitrobenzenesulfonic Acid